CUE BIOPHARMA, INC.
Ownership & governance
Executives 5Directors 5Avg age 61Avg tenure 0.6y
SL
Shao Lee Lin
Chief Executive Officer
Age 59Since 2026-04-29Profile →
+9
Executives5
Board of directors5
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Shao Lee Lin | 8.096 % | 327,537 |
| Bleichroeder LP | 5.618 % | 227,303 |
| GC Wealth Management RIA LLC | 3.816 % | 154,387 |
| Vanguard Capital Management LLC | 2.025 % | 81,914 |
| Lion Point Capital LP | 1.815 % | 73,428 |
Catalog · 2026-07-09
SEC officers11
| Name | Role | Since | Shares |
|---|---|---|---|
| James Ahlers | Chief Financial Officer | — | - |
| Pasha Sarraf | Chairman | — | - |
| Shao Lee Lin | Chief Executive Officer | — | - |
| Daniel Camardo | Director/Board Member | — | - |
| Pamela Garzone | Director/Board Member | — | - |
| Shao Lee Lin | Director/Board Member | — | - |
| Viola Meehan | Director/Board Member | — | - |
| Daniel Baker | Corporate Officer/Principal | — | - |
SEC · as of 2026-07-30
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 88Range 66–115Analysts 3
66Mean 88115
- Buy 3
Broker actions29
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| B. Riley Securities | Initiated | Buy | 83 | 2026-09-18 |
| LUCID CAPITAL MARKETS | Initiated | Buy | 4 | 2025-08-25 |
| Citizens Capital Markets | Reiterated | Market Outperform | 2 | 2025-04-02 |
| Stifel | Maintained | Buy | 4 | 2024-08-20 |
| JMP Securities | Maintained | Market Outperform | 2 | 2024-07-26 |
| Piper Sandler | Maintained | Overweight | 3 | 2024-07-26 |
| Stifel | Maintained | Buy | 8 | 2024-04-09 |
| Oppenheimer | Maintained | Outperform | 10 | 2024-04-09 |
| Piper Sandler | Reiterated | Overweight | 8 | 2024-04-03 |
| Jefferies | Initiated | Buy | 6 | 2024-03-13 |
| Piper Sandler | Maintained | Overweight | 8 | 2023-11-06 |
| Stifel | Reiterated | Buy | 8 | 2023-06-15 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.